<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03990883</url>
  </required_header>
  <id_info>
    <org_study_id>CPH 301-201200F</org_study_id>
    <nct_id>NCT03990883</nct_id>
  </id_info>
  <brief_title>A Clinical Investigation to Evaluate Effectiveness and Safety of Princess FILLER Lidocaine in Correction of Nasolabial Folds (NLF)</brief_title>
  <acronym>FILIDO</acronym>
  <official_title>A Randomized, Subject- and Evaluating Investigator-blinded, Controlled, Multicenter, Split-face, Comparison Clinical Investigation to Evaluate Effectiveness and Safety of Princess FILLER Lidocaine in the Correction of Nasolabial Folds</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Croma-Pharma GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Syneos Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Croma-Pharma GmbH</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Clinical Investigation to demonstrate the effectiveness and safety of Princess Filler&#xD;
      Lidocaine in the correction of moderate to severe nasolabial folds&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Clinical Investigation to assess the effectiveness of &quot;Princess Filler Lidocaine&quot; in reducing&#xD;
      the severity of nasolabial folds compared to &quot;Juvederm Ultra XC&quot;, based on the independent&#xD;
      blinded evaluating investigator live assessment using the Nasolabial Folds Severity Rating&#xD;
      Scale (NLF-SRS) at Week 24 after initial treatment and relative to Baseline assessments&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">June 4, 2019</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Actual">May 29, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Pivotal study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
    <masking_description>subject- and evaluator-blinded</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>independent evaluating investigator live assessment</measure>
    <time_frame>Week 24</time_frame>
    <description>percentage of responders based on the independent evaluating investigators live assessment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>independent photographic reviewers assessment</measure>
    <time_frame>Week 24</time_frame>
    <description>percentage of responders based on the independent photographic reviewers assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>treating investigator live assessment</measure>
    <time_frame>Week 24</time_frame>
    <description>percentage of responders based on the treating investigators live assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement over Baseline - investigator assessment</measure>
    <time_frame>Week 24</time_frame>
    <description>percentage of subjects with improvement based on the independent evaluating investigators assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement over Baseline - subject assessment</measure>
    <time_frame>Week 24</time_frame>
    <description>percentage of subjects with improvement based on the subjects assessment</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">295</enrollment>
  <condition>Dermatological Non-Disease</condition>
  <arm_group>
    <arm_group_label>Treatment of device 1 on left side</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Treatment of nasolabial folds (NLF) with both Investigational Device and Comparator; Princess Filler Lidocaine is assigned to left NLF, Comparator is assigned to right NLF</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment of device 1 on right side</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Treatment of nasolabial folds (NLF) with both Investigational Device and Comparator; Princess Filler Lidocaine is assigned to right NLF, Comparator is assigned to left NLF</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Princess Filler Lidocaine</intervention_name>
    <description>correction of nasolabial folds</description>
    <arm_group_label>Treatment of device 1 on left side</arm_group_label>
    <arm_group_label>Treatment of device 1 on right side</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  over or equal 22 years at screening&#xD;
&#xD;
          -  approximately symmetrical moderate to severe nasolabial folds&#xD;
&#xD;
          -  negative urine pregnancy test&#xD;
&#xD;
          -  healthy skin&#xD;
&#xD;
          -  willing to abstain from aesthetic or surgical procedures in the treatment area&#xD;
&#xD;
          -  written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  pregnant and/or lactating&#xD;
&#xD;
          -  history of allergies or hypersensitivity to e.g. hyaluronic acid preparations&#xD;
&#xD;
          -  tendency to keloid formation&#xD;
&#xD;
          -  HIV positive&#xD;
&#xD;
          -  presence of infectious, inflammatory or proliferative cancerous or pre-cancerous&#xD;
             lesions&#xD;
&#xD;
          -  herpes simplex in treatment area&#xD;
&#xD;
          -  autoimmune or connective tissue disease, immunomodulating therapy&#xD;
&#xD;
          -  uncontrolled diabetes or systemic diseases&#xD;
&#xD;
          -  Facial plastic surgery, tissue augmentation&#xD;
&#xD;
          -  implantation of facial dermal fillers within 12 months&#xD;
&#xD;
          -  Skin of nasolabial region affected by aesthetic treatments&#xD;
&#xD;
          -  Facial lipolysis&#xD;
&#xD;
          -  Bariatric surgery within 12 months&#xD;
&#xD;
          -  History of bleeding disorder&#xD;
&#xD;
          -  Planned dental/oral surgery&#xD;
&#xD;
          -  Any medical condition prohibiting the inclusion according to the investigator&#xD;
&#xD;
          -  Previous enrollment&#xD;
&#xD;
          -  Current participation in another clinical investigation within 30 days prior to&#xD;
             enrollment&#xD;
&#xD;
          -  Dependency of the subject to the investigation site&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Bank, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Center of Dermatology, Cosmetic and Laser Surgery</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Joel Cohen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>AboutSkin research, LLC</affiliation>
  </overall_official>
  <overall_official>
    <last_name>John Joseph, MDE</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dr. John Joseph Facial Plastic and Reconstructive Surgery</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gary Monheit, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Total Skin and Beauty Dermatology Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ava Shamban, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ava MD</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Susan Taylor, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Robert Weiss, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Maryland Laser Skin and Vein</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sabrina Fabi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cosmetic, Lazer, Dermatology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jeanine Downie, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Image Dermatology P.C.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jeremy Green, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Skin Research Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael Gold, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tennesse Clinical Research Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Gary Monheit</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>John Joseph</name>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <zip>91436</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sabrina Fabi</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ava Shamban</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Joel Cohen</name>
      <address>
        <city>Greenwood Village</city>
        <state>Colorado</state>
        <zip>80111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jeremy Green</name>
      <address>
        <city>Coral Gables</city>
        <state>Florida</state>
        <zip>33146</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Robert Weiss</name>
      <address>
        <city>Hunt Valley</city>
        <state>Maryland</state>
        <zip>21030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jeanine Downie</name>
      <address>
        <city>Montclair</city>
        <state>New Jersey</state>
        <zip>07042</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Center for Dermatology Cosmetic and Laser Surgery</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10549</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Susan Taylor</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Michael Gold</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>June 17, 2019</study_first_submitted>
  <study_first_submitted_qc>June 17, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 19, 2019</study_first_posted>
  <last_update_submitted>July 26, 2021</last_update_submitted>
  <last_update_submitted_qc>July 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>nasolabial folds</keyword>
  <keyword>correction</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lidocaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

